AU758150B2 - Antimicrobial/endotoxin neutralizing polypeptide - Google Patents

Antimicrobial/endotoxin neutralizing polypeptide Download PDF

Info

Publication number
AU758150B2
AU758150B2 AU28226/00A AU2822600A AU758150B2 AU 758150 B2 AU758150 B2 AU 758150B2 AU 28226/00 A AU28226/00 A AU 28226/00A AU 2822600 A AU2822600 A AU 2822600A AU 758150 B2 AU758150 B2 AU 758150B2
Authority
AU
Australia
Prior art keywords
polypeptide
cluster
amino acids
endotoxin
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU28226/00A
Other languages
English (en)
Other versions
AU2822600A (en
Inventor
David M. Mann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENDOGEN RESEARCH PH AB
Original Assignee
ENDOGEN RES PH AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ENDOGEN RES PH AB filed Critical ENDOGEN RES PH AB
Publication of AU2822600A publication Critical patent/AU2822600A/en
Application granted granted Critical
Publication of AU758150B2 publication Critical patent/AU758150B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79Transferrins, e.g. lactoferrins, ovotransferrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU28226/00A 1999-02-05 2000-01-27 Antimicrobial/endotoxin neutralizing polypeptide Ceased AU758150B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/245527 1999-02-05
US09/245,527 US6399570B1 (en) 1999-02-05 1999-02-05 Antimicrobial/endotoxin neutralizing polypeptide
PCT/IB2000/000271 WO2000049040A2 (fr) 1999-02-05 2000-01-27 Polypeptide antimicrobien/neutralisant des endotoxines

Publications (2)

Publication Number Publication Date
AU2822600A AU2822600A (en) 2000-09-04
AU758150B2 true AU758150B2 (en) 2003-03-13

Family

ID=22927039

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28226/00A Ceased AU758150B2 (en) 1999-02-05 2000-01-27 Antimicrobial/endotoxin neutralizing polypeptide

Country Status (12)

Country Link
US (2) US6399570B1 (fr)
EP (1) EP1151009B1 (fr)
JP (1) JP2002541066A (fr)
CN (1) CN1362969A (fr)
AT (1) ATE373679T1 (fr)
AU (1) AU758150B2 (fr)
CA (1) CA2362153C (fr)
DE (1) DE60036456T2 (fr)
DK (1) DK1151009T3 (fr)
ES (1) ES2293892T3 (fr)
MX (1) MXPA01007956A (fr)
WO (1) WO2000049040A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US7060677B1 (en) 1999-11-11 2006-06-13 Am-Pharma B.V. Antimicrobial activity of the first cationic cluster of human lactoferrin
EP1507554B1 (fr) * 2002-05-10 2011-08-10 Agennix Incorporated Lactoferrine dans le traitement de tumeurs malignes et autres maladies hyperproliferatives
WO2003099207A2 (fr) * 2002-05-24 2003-12-04 Agennix Incorporated Lactoferrine par voie orale dans le traitement des troubles respiratoires
EP2298338B1 (fr) 2002-09-16 2012-08-22 Agennix Incorporated Compositions à base de lactoferrine et méthodes de traitement des plaies cutanées.
CA2508912A1 (fr) * 2002-12-06 2004-06-24 Agennix Incorporated Lactoferrine orale pour le traitement des sepsies
US7592306B2 (en) * 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US7034126B2 (en) 2003-05-14 2006-04-25 Agennix, Inc. Lactoferrin in the treatment of diabetes mellitus
WO2005046571A2 (fr) * 2003-06-06 2005-05-26 Agennix Incorporated Lactoferrine en tant qu'adjuvant de vaccins contre le cancer
WO2005018542A2 (fr) * 2003-07-10 2005-03-03 Agennix Incorporated Utilisation de lactoferrine dans une prophylaxie dirigee contre une infection et/ou contre une inflammation, chez des patients immunosupprimes
WO2005085287A1 (fr) * 2004-03-03 2005-09-15 En-N-Tech, Inc. Traitements pour la reduction de contaminants dans des preparations de lactoferrines et compositions contenant des lactoferrines
US7183381B2 (en) * 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
MX2008008548A (es) 2005-12-30 2008-09-10 Evonik Roehm Gmbh Peptidos utiles como petidos penetradores de celulas.
EP2050461A1 (fr) 2007-10-19 2009-04-22 PharmaSurgics in Sweden AB Peptides basées sur la séquence de lactoferrin humain et leur utilisation
EP2060586A1 (fr) * 2007-11-14 2009-05-20 PharmaSurgics in Sweden AB Nouveaux peptides synthétiques d'arginine substitué et leur utilisation
US20090209488A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown Compositions for the treatment of exercise induced asthma
US20090208588A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown GERD carbohydrate compositions
US20090209486A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown Compositions of carbohydrates as dietary supplements
US20090209489A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown Compositions for the treatment of diabetis, system PH disorders, high blood pressure, and a cancer marker system
US20090209487A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown Compositions of carbohydrates as dietary supplements
CN101294188B (zh) * 2008-06-20 2011-06-15 江南大学 乳铁蛋白抗菌肽及其制备方法与它们的用途
JP5177901B2 (ja) * 2009-12-02 2013-04-10 株式会社明治 栄養組成物
CN101798337B (zh) * 2010-01-29 2013-04-24 中国人民解放军第三军医大学第一附属医院 内毒素中和肽突变体及其应用
EP2481751A1 (fr) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Homme peptides dérivés de lactoferrine
JP5763024B2 (ja) * 2012-09-07 2015-08-12 株式会社明治 栄養組成物
WO2014124047A1 (fr) 2013-02-06 2014-08-14 Academia Sinica Peptides antimicrobiens issus du domaine riche en arginine de la protéine cœur du virus de l'hépatite b
US20170296629A1 (en) * 2014-10-08 2017-10-19 Keio University Inhibitor of extracellular trap formation in leukocyte
KR101891455B1 (ko) 2014-11-03 2018-08-27 메르크 파텐트 게엠베하 생체분자를 정제하기 위한 가용성 인테인 융합 단백질 및 방법
AU2017270201A1 (en) * 2016-05-27 2018-11-29 Academia Sinica Modified antimicrobial peptide derived from an arginine-rich domain
CN105999236A (zh) * 2016-07-06 2016-10-12 方雅悯 一种治疗牛乳房炎的药剂及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977137B1 (en) 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US6020015A (en) * 1988-09-22 2000-02-01 Gaull; Gerald E. Infant formula compositions and nutrition containing genetically engineered human milk proteins
JP2805490B2 (ja) * 1989-02-07 1998-09-30 雪印乳業株式会社 細菌毒素中和剤
US5141743A (en) * 1989-04-27 1992-08-25 University Technologies International, Inc. Method for isolating and purifying transferrin and lactoferrin receptor proteins and vaccines containing the same
US5571697A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US6100054A (en) 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
IL94183A (en) 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US5571691A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5766939A (en) 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5849881A (en) * 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
US5198419A (en) * 1989-12-08 1993-03-30 Immuno Japan Inc. Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
EP0438750B1 (fr) 1990-01-23 1993-10-27 Morinaga Milk Industry Co., Ltd. Utilisation d'un hydrolysat de lactoferrine comme agent antibactérien
US6066469A (en) * 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
US5240909B1 (en) * 1990-03-14 1998-01-20 Dietrich Nitsche Use of lactoferrin for treatment of toxic effects of endotoxins
DE4008033A1 (de) 1990-03-14 1991-09-19 Nitsche Dietrich Verwendung von lactoferrin zur bekaempfung der toxischen wirkung des endotoxins
JP2818056B2 (ja) 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
ATE148631T1 (de) * 1990-11-13 1997-02-15 Santen Pharmaceutical Co Ltd Therapeutische agens bei hornhautverletzungen
JP3110078B2 (ja) 1991-06-21 2000-11-20 森永乳業株式会社 高純度抗菌性ペプチドの大量製造法
WO1993014640A1 (fr) 1992-01-23 1993-08-05 Morinaga Milk Industry Co., Ltd. Agent antibacterien et traitement d'articles au moyen de cet agent
CA2090658A1 (fr) * 1992-03-02 1993-09-03 Kunio Ando Composition pharmaceutique utilisable pour le traitement ou la prevention de maladies infectieuses opportunistes compliquees d'une infection a lentivirus
ZA932568B (en) 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤
US5733872A (en) 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
JP3770624B2 (ja) 1993-09-02 2006-04-26 雪印乳業株式会社 ウィルス感染・増殖抑制剤
DE69524386D1 (de) * 1994-02-16 2002-01-17 Pharming Intellectual Pty Bv Isolierung von lactoferrin aus milch
NL1000332C1 (nl) 1994-08-31 1996-03-04 Victor Smit Graduele chemische modificatie van biologisch actieve peptiden en eiwitten.
JP3506274B2 (ja) 1994-09-01 2004-03-15 雪印乳業株式会社 新規ペプチドおよび免疫賦活剤
US5531989A (en) * 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
JPH08165248A (ja) 1994-12-15 1996-06-25 Nobuo Kuriiwa エンドトキシンによる炎症の抑止剤
US5712247A (en) * 1995-02-21 1998-01-27 University Of North Carolina Use of lactoferrin to modulate and/or neutralize heparin activity
WO1996031537A1 (fr) * 1995-04-05 1996-10-10 The Picower Institute For Medical Research Agents se liant a des produits finals de glycosylation evolues et leurs methodes d'utilisation
US20020016289A1 (en) * 1995-06-01 2002-02-07 Orla M. Conneely Methods for treatment and prevention of helicobacter pylori infection using lactoferrin
US5834424A (en) * 1995-07-12 1998-11-10 Gambit International Limited Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus
SE506529C2 (sv) * 1996-01-23 1997-12-22 Semper Ab Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
JP2000516812A (ja) * 1996-08-14 2000-12-19 ノバルティス アクチエンゲゼルシャフト 植物病原性真菌に対する阻害活性を有するペプチド
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
JP2002515893A (ja) * 1997-02-03 2002-05-28 ファーミング インテレクチュアル プロパティ ビーブイ ヒトラクトフェリンおよびその改変体の有用な特性
CN1262625A (zh) * 1997-04-10 2000-08-09 阿吉尼克斯股份有限公司 乳铁蛋白在治疗过敏原诱发疾病中的应用
FR2762850B1 (fr) * 1997-05-02 2000-02-11 Biocem Lactoferrines recombinantes, leurs procedes de production par les plantes ainsi que leurs utilisations
US6849593B1 (en) 1997-09-16 2005-02-01 Pharis Biotec Gmbh Bifidogenic peptides
US20020165128A1 (en) * 1998-04-13 2002-11-07 Plaut Andrew G. Compositions and methods for proteolytically inactivating infectious agents using lactoferrin and related molecules
US6451344B1 (en) * 1998-04-30 2002-09-17 Morinaga Milk Industry Co., Ltd. Sugar coated tablets
US6258383B1 (en) * 1998-08-14 2001-07-10 Lactoferrin Products Company Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
US6719973B1 (en) * 1998-12-24 2004-04-13 National University Of Singapore Recombinant proteins and peptides for endotoxin biosensors, endotoxin removal, and anti-microbial and anti-endotoxin therapeutics
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6613741B2 (en) * 1999-10-29 2003-09-02 Ferro Dynamics, Inc. Method for treating aseptic SIRS in humans and other animals
TWI237695B (en) * 1999-12-14 2005-08-11 Joy Biomedical Corp Helicobacter pylori antigens in blood
US20040157277A1 (en) * 2002-03-08 2004-08-12 Clancy Robert Llewellyn Methods for predicting and/or diagnosing the risk of gastric cancer
RU2165769C1 (ru) 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
US7020715B2 (en) * 2000-08-22 2006-03-28 Adaptec, Inc. Protocol stack for linking storage area networks over an existing LAN, MAN, or WAN
KR100454595B1 (ko) * 2001-11-30 2004-10-28 주식회사 이지바이오 시스템 락토페리신 유전자 및 이를 도입한 형질전환 대장균
EP1507554B1 (fr) 2002-05-10 2011-08-10 Agennix Incorporated Lactoferrine dans le traitement de tumeurs malignes et autres maladies hyperproliferatives
WO2003099207A2 (fr) * 2002-05-24 2003-12-04 Agennix Incorporated Lactoferrine par voie orale dans le traitement des troubles respiratoires
SE526038C2 (sv) * 2002-07-08 2005-06-21 Gambro Lundia Ab Polymeraffinitetsmatris, förfarande för framställning därav och anvädning därav
EP2298338B1 (fr) * 2002-09-16 2012-08-22 Agennix Incorporated Compositions à base de lactoferrine et méthodes de traitement des plaies cutanées.
CA2508912A1 (fr) * 2002-12-06 2004-06-24 Agennix Incorporated Lactoferrine orale pour le traitement des sepsies
WO2005003152A1 (fr) * 2003-06-24 2005-01-13 Akzo Nobel N.V. Separation de lipopolysaccharides de complexes proteine-lipopolysaccharide a l'aide de solvants ininflammables
WO2005018542A2 (fr) * 2003-07-10 2005-03-03 Agennix Incorporated Utilisation de lactoferrine dans une prophylaxie dirigee contre une infection et/ou contre une inflammation, chez des patients immunosupprimes
US7183381B2 (en) * 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof

Also Published As

Publication number Publication date
WO2000049040A3 (fr) 2000-12-14
ES2293892T3 (es) 2008-04-01
DE60036456T2 (de) 2008-06-19
CN1362969A (zh) 2002-08-07
CA2362153A1 (fr) 2000-08-24
ATE373679T1 (de) 2007-10-15
WO2000049040A2 (fr) 2000-08-24
US6399570B1 (en) 2002-06-04
EP1151009B1 (fr) 2007-09-19
CA2362153C (fr) 2009-11-24
US7244706B2 (en) 2007-07-17
JP2002541066A (ja) 2002-12-03
DE60036456D1 (de) 2007-10-31
DK1151009T3 (da) 2008-01-28
MXPA01007956A (es) 2004-08-19
AU2822600A (en) 2000-09-04
US20030105006A1 (en) 2003-06-05
EP1151009A2 (fr) 2001-11-07

Similar Documents

Publication Publication Date Title
AU758150B2 (en) Antimicrobial/endotoxin neutralizing polypeptide
JP2002541066A5 (fr)
JP3860838B2 (ja) 抗微生物性陽イオン性ペプチドおよびそのスクリーニング方法
US20240018192A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
CA1341525C (fr) Fragments de proteine d'effet biologique bactericide par accroissement de la permeabilite
Abdolhosseini et al. Lysine substitutions convert a bacterial-agglutinating peptide into a bactericidal peptide that retains anti-lipopolysaccharide activity and low hemolytic activity
KR102137941B1 (ko) 항균 펩티드
CA2155739A1 (fr) Nouveaux peptides antimicrobiens provenant de neutrophiles bovins
Mak et al. The increased bactericidal activity of a fatty acid-modified synthetic antimicrobial peptide of human cathepsin G correlates with its enhanced capacity to interact with model membranes
KR20200098615A (ko) 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체
CN112292143A (zh) 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途
McCrudden et al. The host defence peptide LL-37 is susceptible to proteolytic degradation by wound fluid isolated from foot ulcers of diabetic patients
Saido-Sakanaka et al. Synthesis and characterization of bactericidal oligopeptides designed on the basis of an insect anti-bacterial peptide
CN112368010A (zh) 抗微生物的、细菌噬菌体来源的多肽及其针对革兰氏阴性细菌的用途
US20230052825A1 (en) Antimicrobial and anticancer peptides & conjugates and compositions, methods, articles & kits relating thereto
US20210198644A1 (en) Recombinant lysins
JP2001186887A (ja) サソリ毒由来の抗菌ペプチド
US20150072922A1 (en) Rnase 7 antimicrobial peptides
US20220041666A1 (en) Antimicrobial peptides and compositions, methods, articles & kits relating thereto
Ohno LPS binding proteins in granulocyte lysosomes
JP2022526978A (ja) ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体
WO2002061091A1 (fr) Sequences de nucleotides facilitant l'expression et codant un polypeptide a activite de recepteur de l'hemoglobine tire de porphyromonas gingivalis
Ooi Molecular determinants of action of the bactericidal/permeability-increasing protein
Santamaría Quesada et al. Bactericidal and anti-endotoxic properties of short cationic peptides derived from a snake venom Lys49 phospholipase A2

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PROVIDE SEARCH RESULTS UNDER S45(3) HAS BEEN EXTENDED TO 20040401